Clinical Trial Detail

NCT ID NCT02665416
Title Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

ovarian carcinoma

head and neck squamous cell carcinoma

Advanced Solid Tumor

Therapies

RO5520985 + Selicrelumab

Bevacizumab + Selicrelumab

Age Groups: adult senior

No variant requirements are available.